Keyword: Stada Arzneimittel
The Upsa unit could fit into Stada's new growth strategy, which includes more focus on international marketing of OTC products.
Takeda made two R&D deals, China's crackdown on pollution causes pharma supply issues, Merck KGaA plans production expansions in Asia.
China has closed thousands of manufacturing plants as it tries to reduce air pollution, and one pharma company says it has created supply problems.
Perrigo is looking toward some M&A, with its eye on the consumer health business that Germany’s Merck KGaA has put on the auction block.
Last week, an activist investor held out on the buyout offer for Stada—and it worked.
Hoping to land on its feet after a tough year, Stada will soon be under new leadership.
Two weeks after their bid failed to garner key support from shareholders, Stada’s wannabe buyers are back.
In the wake of last week's canceled buyout, Stada's CEO and CFO have left the company, and new buyout talk has already sprung up.
Weeks after announcing a €5.32 billion ($5.63 billion) buyout, German generics maker Stada said the deal failed to get shareholder approval.
In terms of revenue, Sanofi's generic business was pretty much business as usual—net sales were up 0.7% at constant exchange rate to reach €1.85 billion ($2.05 billion). But the company will sell its European generic unit soon.